CD52 詳細
Molecule Name
CAMPATH-1 antigen
分子の別称
CDW52,HE5,CD52,CAMPATH-1 antigen
Drug Development Progress
治験薬の数5
市販薬剤の数1
研究＆開発段階Approved
ターゲットの別称
Epididymis Secretory Sperm Binding Protein Li 171mP，CD52 Antigen (CAMPATH-1 Antigen)，Epididymal Secretory Protein E5，He5，CDW52 Antigen (CAMPATH-1 Antigen)，CD52 Antigen，HEL-S-171mP，EDDM5，CD52，CDw52，Cambridge pathology 1 antigen，Human epididymis-specific protein 5，CAMPATH-1 antigen，CD52 Molecule
バックグランド
CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a glycoprotein that in humans is encoded by the CD52 gene.It is widely expressed on the cell surface of immune cells, such as mature lymphocytes, natural killer cells (NK), eosinophils, neutrophils, monocytes/macrophages, and dendritic cells (DCs).ligation of cell surface CD52 molecules may offer costimulatory signals for T-cell activation and proliferation.
CD52 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Alemtuzumab biosimilar (Zhangjiang Biotechnology) | Phase 2 Clinical | Shanghai Zhangjiang Biotechnology Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell | 詳細 | |
| ALLO-647 | ALLO-647 | Phase 2 Clinical | Allogene Therapeutics Inc | Carcinoma, Renal Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma | 詳細 |
| Alemtuzumab Biosimilars(Cellectis) | CLLS-52; CLLS52 | Phase 2 Clinical | Cellectis Sa | Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 詳細 |
| Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology) | Phase 1 Clinical | Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd | Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | 詳細 | |
| Alemtuzumab biosimilar(BioXpress) | BX-1523; BXT-1523 | Clinical | Bioxpress Therapeutics Sa | Leukemia, B-Cell; Multiple Sclerosis | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Alemtuzumab | LDP-03; GZ-402673 | Approved | Bayer AG, Genzyme Corp | Campath, Lemtrada, MabCampath | United States | Multiple Sclerosis | Genzyme Corp | 2001-05-07 | Anemia, Aplastic; Anemia, Sickle Cell; Bone marrow transplant rejection; Diabetes Mellitus, Type 1; Fallopian Tube Neoplasms; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Kidney Diseases; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Prolymphocytic, T-Cell; Leukemia, T-Cell; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Mycosis Fungoides; Myelodysplastic Syndromes; Myositis, Inclusion Body; Ovarian Neoplasms; Pancytopenia; Peritoneal Neoplasms; Rejection of renal transplantation; Sezary Syndrome; Waldenstrom Macroglobulinemia | 詳細 |